Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis

被引:78
作者
Atkinson, A [1 ]
Kenny, JR [1 ]
Grime, K [1 ]
机构
[1] AstraZeneca R&D Charnwood, Dept Phys & Metab Sci, Loughborough LE11 5RH, Leics, England
关键词
D O I
10.1124/dmd.105.005579
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Increasing reports of time-dependent inhibition of cytochrome P450 ( P450) suggest further emphasis on interpreting the consequences, either from a pharmacokinetic or toxicological perspective. Two automated, time-dependent inhibition assays with a liquid chromatography-tandem mass spectrometric endpoint are presented. The initial assay utilizes human liver microsomes, a single concentration of inhibitor, and a single preincubation time of 30 min. Phenacetin, diclofenac, S-mephenytoin, bufuralol, and midazolam are used as substrates for CYP1A2, 2C9, 2C19, 2D6, and 3A4, and the assay differentiates between reversible and irreversible inhibition. The second assay uses individual recombinant human P450s, six inhibitor concentrations, and three time points to accurately define k(inact) and K-I. A good correlation is demonstrated between k(inact)/K-I and partition ratio, indicating that both terms are related in describing the efficiency of enzyme inactivation. Despite the single preincubation time point of 30 min used in the initial assay, a good relationship has been found to exist between the unbound IC50 estimated from this initial screen and the k(inact)/K-I ratio derived from the more extensive subsequent single P450 assay. The higher throughput human liver microsomal assay can therefore generate IC50 values that can be used to predict the pharmacokinetic impact on cotherapies from the estimated k(inact)/K-I ratio, predicted human dose, and pharmacokinetics.
引用
收藏
页码:1637 / 1647
页数:11
相关论文
共 40 条
  • [1] The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties
    Austin, RP
    Barton, P
    Cockroft, SL
    Wenlock, MC
    Riley, RJ
    [J]. DRUG METABOLISM AND DISPOSITION, 2002, 30 (12) : 1497 - 1503
  • [2] PARTICULAR ABILITY OF CYTOCHROMES P450 3A TO FORM INHIBITORY P450-IRON-METABOLITE COMPLEXES UPON METABOLIC OXIDATION OF AMINODRUGS
    BENSOUSSAN, C
    DELAFORGE, M
    MANSUY, D
    [J]. BIOCHEMICAL PHARMACOLOGY, 1995, 49 (05) : 591 - 602
  • [3] Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: Comparison with fluoxetine and quinidine
    Bertelsen, KM
    Venkatakrishnan, K
    Von Moltke, LL
    Obach, RS
    Greenblatt, DJ
    [J]. DRUG METABOLISM AND DISPOSITION, 2003, 31 (03) : 289 - 293
  • [4] The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective
    Bjornsson, TD
    Callaghan, JT
    Einolf, HJ
    Fischer, V
    Gan, L
    Grimm, S
    Kao, J
    King, SP
    Miwa, G
    Ni, L
    Kumar, G
    McLeod, J
    Obach, RS
    Roberts, S
    Roe, A
    Shah, A
    Snikeris, F
    Sullivan, JT
    Tweedie, D
    Vega, JM
    Walsh, J
    Wrighton, SA
    [J]. DRUG METABOLISM AND DISPOSITION, 2003, 31 (07) : 815 - 832
  • [5] CARLSON SP, 2002, DRUGS PHARM SCI, V116, P549
  • [6] Chun YJ, 2001, DRUG METAB DISPOS, V29, P389
  • [7] Chun YJ, 2001, CANCER RES, V61, P8164
  • [8] In vitro drug interactions of cytochrome P450: An evaluation of fluorogenic to conventional substrates
    Cohen, LH
    Remley, MJ
    Raunig, D
    Vaz, ADN
    [J]. DRUG METABOLISM AND DISPOSITION, 2003, 31 (08) : 1005 - 1015
  • [9] Fluorometric screening for metabolism-based drug-drug interactions
    Crespi, CL
    Stresser, DM
    [J]. JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2000, 44 (01) : 325 - 331
  • [10] DEMONTELLANO PRO, 1988, PROG DRUG METAB, V111, P99